Viral pathogenesis is the step-by-step process by which a virus enters the body, commandeers host cells, replicates, and causes disease. The immune system fights back with layered defenses, from rapid-response innate sensors that detect foreign genetic material within minutes to slower but precisely targeted adaptive responses involving antibodies and killer T cells. The outcome of any viral infection depends on the tug-of-war between these host defenses and the virus’s own countermeasures, and neither side holds all the cards. Understanding how that contest unfolds explains everything from why a cold resolves in a week to why HIV persists for a lifetime.
How Viruses Get Inside Cells
A virus that cannot enter a cell is harmless. Entry begins with attachment: proteins on the viral surface latch onto specific receptor molecules on the target cell. Which receptors a virus can recognize largely determines which tissues and species it can infect. Enveloped viruses, those wrapped in a lipid membrane, use specialized fusion proteins to merge their envelope with the host cell’s membrane, releasing the viral genome inside.1PubMed Central. Entry of enveloped viruses into host cells: membrane fusion These fusion proteins undergo dramatic shape changes when triggered by receptor binding or the acidic environment inside an endosome, driving a hydrophobic “fusion peptide” into the cell membrane and pulling the two membranes together.2Virology. Viral membrane fusion
Not every virus follows the same playbook. Many viruses need just one or two proteins to get inside, but vaccinia virus, a poxvirus, uses four proteins for cell attachment and twelve more that form a membrane complex dedicated to entry, exploiting both neutral and low-pH routes.3PubMed Central. The membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell components Non-enveloped viruses use entirely different tactics, punching pores in host membranes or exploiting receptor-mediated endocytosis. The diversity of entry strategies is one reason broad-spectrum antiviral drugs are so hard to design.
Hijacking the Host’s Protein-Making Machinery
Once inside, a virus faces a basic logistical problem: it carries no ribosomes. Ribosomes are the cellular machines that read genetic instructions and build proteins, and without them, the viral genome is just inert code. Every virus must co-opt the host cell’s ribosomes to manufacture viral proteins.4PubMed. Translation-A tug of war during viral infection RNA viruses have evolved particularly creative ways of doing this. Some produce molecular structures on their messenger RNA that directly recruit the host’s translation machinery, effectively cutting in line ahead of the cell’s own messages. Others shut down the cell’s normal protein-production pipeline so that only viral messages get read.5PubMed Central. Hijacking the translation apparatus by RNA viruses DNA viruses face the same need but often bring along more of their own molecular tools, including enzymes for copying their genome. Regardless of the strategy, the result is the same: the cell becomes a factory churning out viral components instead of its own.
Innate Immunity and the Interferon Alarm
The body does not wait for a precise identification of the invader before fighting back. Innate immune sensors inside cells detect viral genetic material, whether it is RNA or DNA, in compartments where such molecules do not normally belong. When these sensors fire, they trigger production of type I interferons, signaling proteins that warn neighboring cells to enter an antiviral state and that recruit immune cells to the site of infection.6PubMed. Inborn Errors of Nucleic Acid Sensing and Type I Interferon Signaling Determine Viral Susceptibility in Humans The speed of this interferon response matters enormously. In many acute infections, the first few hours determine whether the virus is contained locally or spreads systemically.
People born with defects in these sensing pathways or in interferon signaling tend to suffer unusually severe viral infections, which underscores how important this first alarm system is. The innate response also primes the adaptive immune system that kicks in days later, so a weak initial response can have cascading consequences.
How Viruses Evade the Innate Alarm
Viruses that could not evade innate immunity would be cleared before they had a chance to spread. As a result, nearly every successful virus carries some form of interferon countermeasure. SARS-CoV-2, for example, encodes multiple proteins that antagonize the interferon response through diverse mechanisms, helping explain why some patients develop high viral loads before the immune system catches up.7Computational and Structural Biotechnology Journal. Immune evasion of SARS-CoV-2 from interferon antiviral system Broadly, viruses can block the intracellular sensors themselves, intercept the signaling cascade downstream of those sensors, or obstruct the response that cells mount after receiving the interferon signal.8PubMed Central. Viral evasion of the interferon response at a glance Influenza, Ebola, herpes simplex, and dengue each deploy different versions of these tricks. The constant evolutionary pressure between viral evasion strategies and host sensing systems is one of the fastest-moving arms races in biology.
Adaptive Immunity and the Role of T Cells
While the innate system holds the line, the adaptive immune system mounts a targeted counterattack. Killer T cells (also called cytotoxic T lymphocytes) scan infected cells for fragments of viral protein displayed on the cell surface. When a killer T cell finds a match, it destroys the infected cell before it can release more virus. These T cells can recognize internal viral proteins that the virus never intended to expose; researchers showed decades ago that human killer T cells recognize the nucleoprotein of influenza A, an internal component, as a major target.9PubMed. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes This means that even if a virus mutates its surface proteins to dodge antibodies, T cells may still catch it by recognizing conserved interior parts.
Helper T cells coordinate the broader response, signaling B cells to mature and produce antibodies. Neutralizing antibodies bind to viral surface proteins and physically block the virus from attaching to or fusing with host cells.10PubMed Central. Neutralizing Antibodies vs. Viruses: Interacting Mechanisms and Escape Tactics But antibodies do more than neutralize. The tail end of an antibody molecule can recruit complement proteins and engage receptors on immune cells like macrophages and natural killer cells, bridging adaptive and innate immunity into a coordinated assault.11PubMed Central. Antibody-mediated control mechanisms of viral infections
T Cell Exhaustion in Chronic Infections
In acute infections like a typical flu, the immune system clears the virus within days to weeks. But in chronic infections such as HIV, hepatitis B, or hepatitis C, the virus persists for months or years, and the immune response pays a price. T cells that are chronically stimulated gradually lose their ability to kill infected cells and produce helpful signaling molecules, a state researchers call exhaustion. Exhausted T cells overexpress inhibitory receptors, show changes in their metabolism and energy production, and shift their gene-expression profiles in ways that make them progressively less functional.12PubMed. Molecular signature of CD8+ T cell exhaustion during chronic viral infection
Understanding exhaustion has had real therapeutic consequences. Drugs called checkpoint inhibitors, originally developed for cancer, work by blocking some of the inhibitory receptors on exhausted T cells, partially restoring their function. Research into reversing exhaustion in the context of chronic viral infections is an active and promising area.13PubMed Central. T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses
Viral Latency and Hidden Reservoirs
Some viruses go a step further than chronic replication: they go silent. Latency means the viral genome persists inside cells but produces little or no protein, making the infected cell effectively invisible to the immune system. Herpesviruses are the textbook example, hibernating in nerve cells or white blood cells and reactivating periodically. HIV integrates its genetic material directly into the host cell’s DNA, creating a latent reservoir primarily in resting memory T cells. Epigenetic modifications, chemical changes that control whether genes are read without altering the DNA sequence itself, play a central role in keeping HIV’s integrated genome quiet.14PubMed Central. Epigenetic Mechanisms of HIV-1 Persistence
Latent reservoirs are the main reason HIV cannot yet be cured with antiretroviral therapy alone. The drugs suppress active viral replication, but the moment treatment stops, virus re-emerges from latently infected cells. Strategies under investigation include “shock and kick” approaches that try to force latent virus out of hiding so the immune system or drugs can destroy it, as well as epigenetic and genetic interventions aimed at permanently silencing or excising the integrated viral DNA.15PubMed Central. Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization
When the Immune Response Itself Causes Harm
The immune system can overreact, and sometimes the virus itself is less dangerous than the inflammatory storm it provokes. In severe COVID-19 and certain other infections, excessive release of inflammatory signaling molecules creates what is often called a cytokine storm. One key driver is interleukin-6, which can damage the lining of blood vessels by disrupting the junctions between cells, promoting leakage of fluid into tissues and activating the clotting cascade in ways that lead to dangerous blood clots.16Experimental & Molecular Medicine. Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms This helps explain why some patients with severe viral pneumonia die not from the virus destroying lung tissue directly, but from their own immune response causing widespread organ damage.
Recognizing the role of immunopathology has changed treatment. Drugs that block interleukin-6 signaling or dampen inflammation more broadly are now used alongside antivirals in certain severe infections, a strategy that would seem paradoxical if you thought of infection purely as a battle between virus and host.
Viruses and the Brain
The brain is normally shielded from pathogens by the blood-brain barrier, a tightly sealed layer of cells lining the brain’s blood vessels. Neurotropic viruses, those that can infect nerve tissue, breach this barrier through several routes: squeezing between cells, passing directly through them, or hitching a ride inside immune cells that cross the barrier on routine patrol, a strategy sometimes called the “Trojan horse” mechanism.17PubMed. Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis Once inside the brain, the virus can trigger both protective and destructive immune responses. The inflammatory response tends to further weaken the blood-brain barrier, allowing more immune cells and potentially more virus to enter, while type I interferon signaling helps stabilize the barrier.18PubMed Central. Immune response and blood-brain barrier dysfunction during viral neuroinvasion HIV provides a stark illustration: several of its proteins directly degrade the tight-junction proteins holding barrier cells together, causing chronic low-level neurological damage even when the virus is otherwise well controlled by medication.17PubMed. Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis
Viruses That Cause Cancer
A handful of viruses can set cells on the path to cancer, a process called viral oncogenesis. Tumor viruses push cells toward uncontrolled growth by disabling the molecular brakes that normally prevent it. They often do this by targeting tumor suppressor proteins. The hepatitis B virus protein HBx, for instance, binds to the tumor suppressor p53 in the cytoplasm, preventing p53 from entering the nucleus where it would normally trigger cell death or DNA repair. HBx also inactivates another tumor suppressor, pRb, causing cell-cycle changes that promote the development of liver cancer.19Signal Transduction and Targeted Therapy. Viral oncogenesis in cancer: from mechanisms to therapeutics
The common thread across tumor viruses, whether hepatitis B, human papillomavirus, Epstein-Barr virus, or others, is that chronic persistent infection drives the process. The infected cells are not immediately cancerous; rather, the virus’s ongoing interference with cell-cycle controls and immune surveillance accumulates over years or decades, eventually tipping cells into malignancy.20PubMed Central. Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention Vaccination against these viruses (the hepatitis B vaccine, the HPV vaccine) is therefore a form of cancer prevention, one of the more remarkable achievements of modern medicine.
Why People Respond So Differently to the Same Virus
Two people infected with the same virus can have wildly different outcomes, and genetics is a big part of the reason. The HLA system, a large family of genes that encode the molecules cells use to display viral fragments to T cells, is among the most variable in the human genome. Different HLA variants present different viral fragments, so a person’s HLA type influences how effectively their T cells recognize and fight a given virus. A large genome-wide study identified 40 independent signals in the HLA class II region that shaped antibody responses to common viruses including Epstein-Barr virus, varicella-zoster virus, and Merkel cell polyomavirus, along with seven novel genetic loci outside HLA.21PubMed Central. The landscape of host genetic factors involved in immune response to common viral infections
For COVID-19 specifically, carriers of the HLA-B*07:02 allele showed roughly 2.5-fold higher susceptibility, while those with HLA-B*15:01 appeared to have lower susceptibility.22Scientific Reports. Association of HLA-B gene polymorphism and blood groups with COVID-19 susceptibility and severity Across many infectious diseases, from tuberculosis to hepatitis C, HLA variation is one of the strongest genetic predictors of who gets severely ill and who shrugs off infection.23PubMed Central. Human Leukocyte Antigen (HLA) System: Genetics and Association with Bacterial and Viral Infections
Antigenic Drift and the Virus’s Escape Route
Viruses, particularly RNA viruses, copy their genomes with far less accuracy than human cells copy DNA. The result is that within a single infected person, the virus exists not as a single uniform population but as a swarm of closely related variants, often called a quasispecies.24PubMed Central. RNA Viruses and RNAi: Quasispecies Implications for Viral Escape When the immune system or an antiviral drug applies pressure, mutants that happen to dodge that pressure have an advantage and can rapidly expand. This is how influenza evolves to evade last year’s antibodies, how HIV develops drug resistance, and how SARS-CoV-2 spawned new variants. Modeling this process shows that even a single founder virus can generate enough diversity through mutation to produce immune-escape variants during the course of one infection.25PubMed Central. A quantitative quasispecies theory-based model of virus escape mutation under immune selection
Trained Innate Immunity
The textbook distinction used to be clean: innate immunity is fast but lacks memory, while adaptive immunity is slow but remembers past infections. That boundary has blurred. Research over the past decade has shown that innate immune cells can develop long-term functional changes after an initial encounter with a pathogen or a vaccine, a phenomenon called trained immunity. This “memory” is not driven by the gene rearrangement that gives T and B cells their specificity. Instead, it involves epigenetic reprogramming, lasting changes in how genes are read that alter how those cells respond to future challenges.26PubMed Central. Trained immunity: A program of innate immune memory in health and disease
One practical implication is that certain vaccines may offer protection beyond their intended target. The BCG tuberculosis vaccine, for instance, has been shown to reduce the incidence of unrelated respiratory infections, an effect attributed to trained immunity rather than cross-reactive antibodies.27Trends in Molecular Medicine. Viral Pathogenesis and Immune Responses: A Comprehensive Overview On the flip side, inappropriate activation of trained immunity by the body’s own signals may contribute to chronic inflammatory diseases and even neurodegenerative conditions.28PubMed. Trained innate immunity: Concept, nomenclature, and future perspectives
Antiviral Drug Strategies and Why Resistance Develops
Most antiviral drugs work by targeting a specific viral protein, such as a polymerase or protease, that the virus needs to replicate. The problem is that because viruses mutate so quickly, resistance to any single drug can emerge fast. Direct-acting antivirals against enteroviruses, including capsid-binding compounds and protease inhibitors, have failed in clinical trials due to limited efficacy or toxicity.29PubMed Central. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections
An alternative strategy targets host cell factors that the virus depends on rather than the virus itself. Because the virus cannot easily mutate to replace a missing host function, the chance of resistance emerging is much lower. Genome-wide screening tools have identified host factors that are critical for viral replication but dispensable for the cell, making them attractive drug targets.30PubMed Central. Host-Directed Antiviral Therapy Host-directed approaches also have the potential for broad-spectrum activity, since unrelated viruses sometimes rely on the same cellular pathways. The trade-off is a higher risk of side effects, since you are interfering with a human protein rather than a viral one.
Ancient Viral DNA Inside Us
Roughly 8% of the human genome consists of sequences inherited from retroviruses that infected our ancestors millions of years ago. Over evolutionary time, these endogenous retroviruses accumulated mutations that rendered them non-infectious, and in some cases, the host genome co-opted them into useful roles.31PubMed Central. Endogenous Retroviruses as Modulators of Innate Immunity One of the most striking examples involves the interferon response itself. Researchers found that endogenous retroviral elements have spread interferon-inducible enhancers throughout mammalian genomes. When they deleted a subset of these elements from human cells using gene editing, the expression of nearby interferon-stimulated genes dropped, and essential immune functions, including activation of a key inflammasome, were impaired.32PubMed Central. Regulatory evolution of innate immunity through co-option of endogenous retroviruses In other words, sequences that originated in ancient viruses now serve as regulatory switches for the very immune pathways that defend us against modern viruses.
Zoonotic Spillover and the Species Barrier
Most emerging infectious diseases originate in animals. For a virus to jump from one species to another, it must overcome a series of molecular barriers: recognizing receptors on the new host’s cells, evading the new host’s immune defenses, and replicating efficiently enough to sustain transmission. Each of these barriers can be thought of as a gate that the virus must pass through, with receptor recognition, immune evasion, and genomic flexibility as the core drivers of whether spillover succeeds.33Animal Diseases. Molecular mechanisms of viral host tropism and cross-species adaptation: a sequential molecular gatekeeping model of spillover
H5N1 avian influenza illustrates how these gates can weaken. Recent infections in mink, sea lions, domestic cats, and cattle suggest the species barrier is eroding, with specific mutations enhancing the virus’s ability to replicate in mammalian cells and bind mammalian respiratory receptors.34PubMed. The emerging pandemic threat of H5N1: Evolutionary adaptations for human transmission, zoonotic spillovers and surveillance gaps Surveillance systems that track these molecular changes in animal populations are one of the few tools available for early warning before a spillover becomes a pandemic.
The Placenta as a Viral Battleground
Pregnancy creates a unique immunological situation. The placenta must tolerate the genetically foreign fetus while still defending against pathogens. Several viruses can breach the placental barrier, including rubella, cytomegalovirus, Zika, and parvovirus B19, with consequences ranging from miscarriage to birth defects.35PubMed. Congenital Viral Infection: Traversing the Uterine-Placental Interface Recent research has examined how SARS-CoV-2, Zika, and cytomegalovirus penetrate placental defenses and damage the developing fetus, revealing shared pathways that could serve as therapeutic targets.36PubMed Central. The placental battlefield: viral strategies and immune countermeasures The gut microbiome also feeds into this broader picture of immune readiness: with the majority of immune cells residing in the gut, the composition of intestinal bacteria influences both local mucosal defenses and systemic immune tone, shaping how the body responds to viral challenges at every stage of life.37PubMed Central. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies
Single-Cell Technologies and What They Are Revealing
Much of what researchers knew about immune responses to viruses came from studying bulk populations of cells, which averages out the behavior of millions of individual cells into a single measurement. Single-cell RNA sequencing has changed that. By reading the gene activity of individual cells, researchers can now identify rare cell types, track how specific immune cells change during infection, and discover cellular states that were previously invisible. Studies using this technology during the COVID-19 pandemic mapped the immune landscape across patients with moderate and severe disease, revealing how different immune cell populations expand, contract, or become dysfunctional as the disease progresses.38Nature Immunology. Single-cell landscape of immunological responses in patients with COVID-19 Similar approaches applied to HIV, hepatitis B, influenza, and respiratory syncytial virus are uncovering previously unrecognized cellular states and remodeling of the immune landscape that standard methods missed.39PubMed. Deciphering viral infections at single-cell resolution: From immune dynamics to host-pathogen interactions The resolution these tools provide is beginning to explain why two patients with the same virus and similar risk profiles can end up with very different outcomes, and it is generating a list of new therapeutic targets in the process.